Maximizing Emerging Technology’s Potential

1. Maximizing Emerging Technology’s Potential Chris L. Waller, Ph.D.October 2011

2. Outline • Industry Drivers for Change • Vertical Disintegration and Selective Sourcing • The Pistoia Alliance • A Pre-competitive Technology Development Experiment • eHealth • A Transformative Opportunity for Pharma Driven by Emerging Technologies • Pharma 2.0 • The Emerging Research Alliance Network Model and The Importance of Technology Partners

3. Target Selection Chemical Selection Clinical Trials Launch Discovery(2-10 years) Pre-clinical TestingLaboratory and animal testing Phase 120-80 healthy volunteers - safety and dosage Phase 2 100-300 patient volunteers efficacy & safety Phase 33,000-5,000 patient volunteers used to monitoradverse reactions to long-term use FDA Review/Approval Years 0 2 4 6 8 10 12 14 16 Cost = $1.3B/new drug R&D: Long, Expensive, and Risky

4. Productivity is Decreasing Source: Tufts Center for the Study of Drug development, PhRMA

5. Industry Driver: Externalization Cost pressures, disruptive technologies, and other forces often drive business processes to be externalized. Fully Internal Model Selectively Integrated Model

6. Opportunities Academia Co-PIs, Institutions Biotech Partnerships, JBVs Pharma Alliances, Acquisitions

7. Opportunities Academia Tech. Transfer, Start-ups Biotech Tech. Transfer, Acquisitions Pharma

8. Pistoia Alliance:Description and Purpose Mission To streamline pre-competitive workflow elements of pharmaceutical research and development by specifying common business terms, relationships and processes • Goal • Develop taxonomies and vocabularies, application interface specifications, data dictionaries, data models, etc. • Establish standards that will be embraced by producers and consumers of pre-competitive workflows

9. Pistoia Alliance: Membershipas of: August 26, 2009 >65 Individuals from 18 member organizations

10. Holographic Storagec Smart Apps Digital Paper SaaS PaaS SOA Semantic Web Webservices Digital Workflow Cloud computing IaaS 3D UI IPv6, IPSec 4G, LTE VOIP Device Convergence Smartphones XMPP Social Networks Quantum Cryptography Mobile Payments Personal Agents Mobile Broadcast Ultra WideBand Ambient Networking Internet of Thingsc Search Mobile IP wiMax GPS Now 2011 Senor Nets(atom+, Zigbee, Blue Lite) Nano Photonics Biometric Senors Behavior Sensors Optical Diagnostics Nanofibers Low Power Senors RFID Imaging sensors 2012 2015 2020+ DNA Sequencing Molecular Imaging Microfuidics BioPhotonics Microarrays OpenSource (Hadoop, Crossbow) Social Mining Utility Computing Predictive Models Grid Computing BioMedical Modeling Real-time analytics Technologies Health Outcomes Registries DTC Genetic Testing Rapid Diagnostic Kits Personal Genome Record RxAuthentication PreImplantationGenetic Diagnosis Personal Wellness Plans Remote Monitoring Dx-Rx Kits Health Xchanges Telehealth EHR Unified Communications Solution/Service/Product Communities Self Monitoring Health devices Portals EMR E-mail Telemedicine Biomarker PHR Personal Assist Devices Technology Trends Supporting eHealth Digitization of Health Information Digitization of Health Communication Decreasing Costs of Sensors Decreasing Cost of DNA Sequencing Increased Computational Analytics Capabilities

11. eHealth Focused Portfolio Well Being / Nokia / iPhone Patient-centric Provider-centric Health & Wellness Consumer Electronics Care provision augmentation 1a 2a Business Diversification beyond Pharma New Product and Services Health & Wellness Self-Management Services Clinical Decision Support Aids 1b 2b Keas PACeR DAER/ASTER Uses of Clinical Data for R&D Adverse Event Reporting Utility Health Economics Analytics 3a Business Innovation within Pharma Clinical Data Flow and Uses 3b Maccabi 3c eHealth Strategic Priority Areas for 2010 need to be developed and validated in concert with the BUs, RUs, Divisions, and the Leadership Team

12. The Evolving Pfizer R&D Ecosystem • Evolving paradigm for the discovery of medicines (Collaborative) • A vision that points towards open innovation and collaborations • Open research model to collectively share scientific expertise • Enhance speed of drug discovery beyond individual resource capabilities (Speed) • Limited research budgets and capabilities driving greater shared resources • Goal to see all partners succeed by accelerating the SCIENCE • Synergize Pfizer’s strengths with Research Partners (Knowledge) • Pair Pfizer’s design, cutting edge tools, synthetic excellence with research partners (academics, not-for-profits, venture capitalists, or biotechs) to develop break through science, novel targets, and indications of unmet medical need • Current example of academic and not-for-profits partners (Discover and Publish) • Drive to publish in top journal with science receiving high visibility and interest a few months ago we entered into a collaboration with the giant pharmaceutical industry Pfizer to test some of their leading molecules for potential relevance to HD. Body clock mouse study suggests new drug potential Mon, Aug 23 2010 By Kate Kelland LONDON (Reuters) - Scientists have used experimental drugs being developed by Pfizer to reset and restart the body clock of mice in a lab and say their work may offer clues on a range of human disorders, from jetlag to bipolar disorder. • Contacts: • Travis Wager (travis.t.wager@pfizer.com) • Paul Galatsis (paul.galatsis@pfizer.com)

13. Emerging Technology Watch List Horizon 1 Horizon 2 Horizon 3 • Mobility • Digital Platforms • Enterprise Federated Infrastructure Integration Services Collaboration and Interconnectivity Disruptive Business Innovation